We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+48.43%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.61B
AUM Growth
+$2.03B
Cap. Flow
+$675M
Cap. Flow %
12.03%
Top 10 Hldgs %
60.15%
Holding
73
New
17
Increased
18
Reduced
15
Closed
18

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$124M
2
VERA icon
Vera Therapeutics
VERA
+$100M
3
GRAL
GRAIL Inc
GRAL
+$88.4M
4
ALKS icon
Alkermes
ALKS
+$59.9M
5
SLNO
Soleno Therapeutics
SLNO
+$54.8M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$190M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$159M
3
TERN
Terns Pharmaceuticals
TERN
+$155M
4
ETNB
89bio
ETNB
+$138M
5
GH icon
Guardant Health
GH
+$121M

Sector Composition

Rank Sector Weight
1 Healthcare 78.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
26
Alkermes
ALKS
$8.82B
$56M 1%
+2,000,000
New +$59.9M
DYN icon
27
Dyne Therapeutics
DYN
$4.04B
$51.8M 0.92%
2,650,000
+650,000
+33% +$12.3M
CLDX icon
28
Celldex Therapeutics
CLDX
$2.77B
$51.6M 0.92%
1,900,738
-99,262
-5% -$2.61M
CMPS
29
Compass Pathways
CMPS
$1.52B
$50.6M 0.9%
7,334,323
-525,325
-7% -$3.2M
CNTA
30
DELISTED
Centessa Pharmaceuticals
CNTA
$50M 0.89%
+2,000,000
New +$50.7M
SLNO
31
DELISTED
Soleno Therapeutics
SLNO
$46.3M 0.83%
+1,000,000
New +$54.8M
VSTM icon
32
Verastem
VSTM
$532M
$44.3M 0.79%
+5,740,850
New +$51.2M
BCAX
33
Bicara Therapeutics
BCAX
$1.78B
$44M 0.78%
2,614,004
+187,347
+8% +$3.2M
GERN icon
34
Geron
GERN
$911M
$42.9M 0.77%
32,511,271
-8,585,251
-21% -$10.8M
ENGN icon
35
enGene Therapeutics
ENGN
$122M
$39.5M 0.7%
4,377,572
+2,138,219
+95% +$17.1M
ANIP icon
36
ANI Pharmaceuticals
ANIP
$1.77B
$37.7M 0.67%
477,684
+27,684
+6% +$2.4M
TERN
37
DELISTED
Terns Pharmaceuticals
TERN
$31.1M 0.55%
769,048
-6,725,952
-90% -$155M
ENTA icon
38
Enanta Pharmaceuticals
ENTA
$372M
$30.9M 0.55%
+1,956,867
New +$24.9M
DFTX
39
Definium Therapeutics
DFTX
$5.73B
$22.4M 0.4%
1,676,540
+176,540
+12% +$2.18M
TNGX icon
40
Tango Therapeutics
TNGX
$4.34B
$21.7M 0.39%
2,454,562
+1,000,000
+69% +$8.62M
XFOR icon
41
X4 Pharmaceuticals
XFOR
$363M
$20.1M 0.36%
5,013,661
+3,891,177
+347% +$14.1M
ATAI icon
42
AtaiBeckley Inc
ATAI
$2.66B
$19.1M 0.34%
+4,677,289
New +$22.1M
XENE icon
43
Xenon Pharmaceuticals
XENE
$6.32B
$16.4M 0.29%
366,435
-833,565
-69% -$35M
COGT icon
44
Cogent Biosciences
COGT
$6.79B
$16.1M 0.29%
+453,102
New +$12.7M
HELP
45
Cybin Inc
HELP
$472M
$15.2M 0.27%
1,854,255
+854,255
+85% +$5.5M
CNTX icon
46
Context Therapeutics
CNTX
$56.4M
$10.9M 0.19%
7,419,355
– –
MNPR icon
47
Monopar Therapeutics
MNPR
$736M
$6.23M 0.11%
+95,408
New +$7.8M
BHVN icon
48
CALL
Biohaven
BHVN
$2.16B
$5.64M 0.1%
+500,000
New +$6.19M
CBIO
49
Crescent Biopharma
CBIO
$602M
$5.38M 0.1%
453,686
– –
ALGS icon
50
Aligos Therapeutics
ALGS
$25.2M
$4.14M 0.07%
444,110
– –
1
2
3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
GA
Greenhaven Associates Purchase, New York $6.07B AUM 11.2% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return

Deep Track Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Deep Track Capital held 73 positions worth $5.61B, up 57% from $3.58B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Deep Track Capital deployed $675M of net new capital in Q4 2025, opening 17 new positions and adding to 18 existing holdings. Its largest new stake was Vera Therapeutics: 2,821,135 shares worth $143M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $159M trimmed.

  • Deep Track Capital's largest Q4 2025 buy was Vera Therapeutics: 2,821,135 shares worth $143M.
  • Deep Track Capital added most to BioMarin Pharmaceuticals in Q4 2025, an estimated $124M increase.
  • Deep Track Capital's biggest Q4 2025 reduction was Ionis Pharmaceuticals, cutting an estimated $159M.
  • Deep Track Capital fully exited Akero Therapeutics in Q4 2025, selling an estimated $190M.
  • Deep Track Capital's ten largest holdings make up 60% of its $5.61B portfolio in Q4 2025.
  • Deep Track Capital opened 17 new positions and closed 18 in Q4 2025.
  • Deep Track Capital's portfolio value rose 57% quarter-over-quarter to $5.61B.

Based on Deep Track Capital's 13F filing for Q4 2025, filed 13 Feb 2026.